Recipient of the 2022 Seldin~Smith Award for Pioneering Research: Piro Lito, MD, PhD

Dr. Lito

The American Society for Clinical Investigation (ASCI) is pleased to recognize Piro Lito, MD, PhD, as the recipient of the 2022 Donald Seldin~Holly Smith Award for Pioneering Research. Dr. Lito receives an honorarium of $30,000 to advance his academic efforts and will deliver a scientific talk at the 2023 AAP/ASCI/APSA Joint Meeting.

Dr. Lito has worked to understand KRAS oncoprotein signaling in cancer. Approximately 25% of patients with lung cancer have KRAS mutations; and ~13% of these have the specific mutation G12C. Dr. Lito demonstrated that KRAS mutants are not locked in their active state but rather cycle between their active and inactive states in cancer cells. Further, he described the mechanism by which KRAS G12C can be inhibited by drugs that target its inactive state, rendering it unable to contribute to further tumor growth. In addition, Dr. Lito co-led the first-in-human clinical trial of the KRAS G12C inhibitor sotorasib, work that paved the way for the US FDA’s approval of sotorasib in 2021.

Frank McCormick, PhD, FRS, DSc (Hon), who is Professor, UCSF Helen Diller Family Comprehensive Cancer Center, supported Dr. Lito’s nomination, noting that “Piro is exemplary of the kind of person we should support with the Seldin~Smith Award. He has tremendous potential to conduct high‐risk and potentially groundbreaking research.”

Dr. Lito earned his BS, PhD, and MD from Michigan State University. He subsequently completed his internship and residency in internal medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School. He did his clinical fellowship in medical oncology and postdoctoral research at the Memorial Sloan Kettering Cancer Center, where he is currently Associate Member and Attending Physician. Dr. Lito’s research has been supported in part by the National Cancer Institute. He is a Pew-Stewart Scholar in Cancer Research, a Damon Runyon Clinical Investigator, a recipient of the 2018 ASCI’s Young Physician-Scientist Awards, and the recipient of the 2021 Trailblazer Prize for Clinician Scientists by the Foundation of the National Institutes of Health. He was elected to the ASCI in 2021. 

Nominations were evaluated by the Seldin~Smith Award Selection Committee: Mukesh K. Jain (Chair), Vivian G. Cheung, Charles L. Sawyers, Elizabeth M. McNally, W. Kimryn Rathmell, and Lorraine Ware. Finalists were evaluated by an Advisory Committee comprising five physician-scientist luminaries: Joseph L. Goldstein (Chair), Michael S. Brown, Robert J. Lefkowitz, Christine Seidman, and Arthur Weiss.

Message from Sohail Tavazoie, the incoming 2022-2023 President

Dr. Tavazoie

I am incredibly honored to start my term as ASCI President. My four years on Council revealed to me the critical roles our members and organization play in benefiting society. The scientific study of human disease improves human health, enhances our fundamental understanding of biology, supports our economy, spawns new and previously unforeseeable disciplines, and is the most privileged profession imaginable for many of us.

It is my hope that we will better support and enable current and future physician-scientists to have the opportunities we’ve had so they can make the transformative discoveries of tomorrow. To this end, we wish to hear from you. We will be sending members a survey to inform our Council about the needs, challenges, and aspirations of our members and their physician-scientist trainees. I have also begun an initiative to highlight and promote the scientific and personal histories of our membership. To do this, we will be requesting your research interests, recent key publications, and a short video, all of which will be posted on an updated ASCI website and directory. This will serve to inspire physician-scientist trainees, enhance their recruitment into members’ labs, and foster interactions, collaborations, and support networks in our community.

We will also soon announce the details of two awards aimed at recognizing outstanding mid-career members, and we are planning additional initiatives to nurture the careers of physician-scientist trainees and junior faculty members.

You can follow these developments on Twitter @the_asci, @AsciPresident, the JCI @jclinicalinvest, and JCI Insight @jci_insight.

Sincerely,

Sohail Tavazoie, MD, PhD

Message from Hossein Ardehali, the outgoing 2021-2022 President

Dr. Ardehali

I have completed my 2021-2022 Presidential term and am grateful for the trust the membership placed in me by electing me to serve in this special capacity. It has been a true and humbling honor for me, having immigrated as a teenager from war-torn Iran to the US, where I was able to pursue the physician-scientist career path. In my Presidential Address at April’s Joint Meeting, I talked about my personal history as an immigrant but more importantly the significance of immigration to science and technology in the US, which I hope will continue to be a symbol of freedom and remain open to the world. (Watch the video.)

I’m pleased that we were able to accomplish the following initiatives during my term:

  • We created the ASCI Scientific Sessions, monthly presentations from accomplished investigators, free and open to all, through the academic year. We started in September 2021 with Dr. Bill Kaelin and finished this cycle with Dr. Charles Sawyers. (See the 2021-2022 archive.) The 2022-2023 ASCI Scientific Sessions will start in September 2022.
  • We increased programming for early-career physician-scientists, including the ASCI’s Physician-Scientist Pathway Series, a periodic informal discussion between a senior ASCI member and the ASCI’s early-career awardees (more below). Thank you to Drs. Miriam Merad and Sangeeta Bhatia for their participation as we started this Series.
  • We strengthened international outreach, notably to the Association of Physicians of Great Britain and Ireland, with ongoing discussion regarding tangible collaborations between our respective groups.
  • We started a quarterly summary of ASCI activities and information (this email being a continuation of that initiative).

I give my thanks to Drs. Lorraine Ware, Kim Rathmell, and Kieren Marr, who preceded me when I started on the Presidential path and who provided great examples of leadership, and to the many Council members with whom I’ve served since being elected to the Council in 2016. All have contributed significant time and effort to ensure the ASCI’s success. I also want to thank my friend and colleague, John Hawley, and the rest of the ASCI staff for their continuous support and for their hard work in the past year. Dr. Sohail Tavazoie succeeds me as 2022-2023 President. Join me in wishing him the best for his term.

Sincerely,

Hossein Ardehali, MD, PhD @ArdehaliHossein